In two different studies, rollout of doxyPEP yielded reductions of 50%–80% in incidence of chlamydia and syphilis.
Doxycycline postexposure prophylaxis (doxyPEP; 200 mg within 72 hours after condomless sex) reduces risk for bacterial sexually transmitted infections (STIs). Clinical trials in men who have sex with men (MSM) and in transgender women (TGW) showed that this approach led to marked reductions of both chlamydia and syphilis. Now, investigators assessed the effectiveness of this intervention in two studies conducted in northern California.
Among 11,551 enrollees in Kaiser Permanente Northern California who were using HIV preexposure prophylaxis (PrEP), 20% were given doxyPEP. In a retrospective cohort study of STI positivity among doxyPEP recipients before versus after execution of this intervention, quarterly incidence of chlamydia fell by 79%,…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)